[Video]

 Daisaku Sato

Director, Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency (PMDA)

"The Japanese government supports the exchanges and cooperation in medicine between China and Japan, and has given substantial support in terms of funding, policies, and technology." Daisaku Sato, Director of the Office of Cellular and Tissue-based Products, PMDA, said. The 2019 China-Japan Advanced Medical and New Drug R&D Summit and Achievements Transformation Conference have gained the attention and affirmation of the Japanese government and experts.

He said that in recent years, most of the breakthroughs in Japan’s new drug R&D have been regenerative medicine and genetics, and they have developed rapidly. The transformation of medical achievements requires practice. In Japan and China, the commercialization of research achievements must be regulated and follow certain procedures. As medical cooperation between both countries becomes more frequent, the Japan hopes to work with China and formulate common procedures for commercialization of products and achievements from both sides so that patients can enjoy the benefits.

As Japan's national drug administration, PMDA's approval rate for new drugs has doubled compared with 10 years ago, and the number of approvers is three times that of 10 years ago. "The biggest challenge is that some of the examiners’ expertise is not as sufficient as expected, so we want them to improve professional capability and hope to recruit more professionals in biomedical fields."

Source: The Cover

© SCIMEA and The Cover